On April 23, 2021, the Board of Directors of Finch Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board from seven members to eight members and elected Susan Graf to its Board, effective immediately, to serve as a Class II director whose term will expire at the Company’s 2023 Annual Meeting of Stockholders. On April 23, 2021, Ms. Graf was also appointed to serve as the chairperson of the Audit Committee of the Board. Dominic Ferrante, the prior chairperson of the Audit Committee, will continue to serve as a member of the Audit Committee. In connection with Ms. Graf’s appointment to the Audit Committee, Nicholas Haft resigned as a member of the Audit Committee. Mr. Haft will continue as a member of the Board.